Payment overview · 2025
General Payments
$1,657.29
78 reported records · 24 companies
Healthcare provider profile · identity verified
John Smyth Michel, DO
Allopathic & Osteopathic Physicians|General Practice · PHILADELPHIA, PA · NPI 1164697124
Verified facts
What the public records show
CMS Open Payments records show John Smyth Michel, DO received $1,657.29 in general payments during 2025 across 78 reported records.
ABBVIE INC. accounted for 11.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 555 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 600 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 2054 claims for Eliquis by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 600 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 455 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 2054 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $189.94 | 11.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $165.34 | 10.0% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $131.89 | 8.0% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $113.11 | 6.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $102.64 | 6.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $99.44 | 6.0% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $92.91 | 5.6% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $90.49 | 5.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.26 | 5.4% | 5 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $79.84 | 4.8% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $64.08 | 3.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.52 | 3.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.48 | 3.6% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $47.48 | 2.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.16 | 2.5% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.21 | 2.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.09 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.81 | 1.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $25.26 | 1.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.75 | 1.5% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $23.39 | 1.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.98 | 1.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.19 | 0.9% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $15.03 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,657.29 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $115.87 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $113.11 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $99.44 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $90.49 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $79.84 | 4 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $67.27 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $64.08 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.86 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $60.20 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.48 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.44 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.09 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $35.56 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.09 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.07 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 600 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 150 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 292 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 311 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
150 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
555 | 132 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
600 | 130 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
2054 | 221 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
311 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
600 | 130 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
455 | 85 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
292 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
2054 | 221 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
180 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 4453 | 998 |
| Amlodipine Besylate | Amlodipine Besylate | 2556 | 553 |
| Gabapentin | Gabapentin | 2256 | 390 |
| Eliquis | Apixaban | 2054 | 221 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 2002 | 385 |
| Metformin Hcl | Metformin Hcl | 1580 | 364 |
| Furosemide | Furosemide | 1474 | 292 |
| Losartan Potassium | Losartan Potassium | 1411 | 336 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1293 | 230 |
| Lisinopril | Lisinopril | 1234 | 306 |
| Carvedilol | Carvedilol | 1143 | 219 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1118 | 225 |
| Metoprolol Succinate | Metoprolol Succinate | 1107 | 240 |
| Omeprazole | Omeprazole | 889 | 216 |
| Mirtazapine | Mirtazapine | 882 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 827 | 144 |
| Trazodone Hcl | Trazodone Hcl | 822 | 129 |
| Quetiapine Fumarate | Quetiapine Fumarate | 726 | 113 |
| Levetiracetam | Levetiracetam | 713 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 692 | 164 |
| Sertraline Hcl | Sertraline Hcl | 689 | 95 |
| Xarelto | Rivaroxaban | 678 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 663 | 123 |
| Nifedipine Er | Nifedipine | 636 | 158 |
| Simvastatin | Simvastatin | 625 | 142 |
| Metoprolol Tartrate | Metoprolol Tartrate | 622 | 125 |
| Baclofen | Baclofen | 602 | 82 |
| Jardiance | Empagliflozin | 600 | 130 |
| Ibuprofen | Ibuprofen | 588 | 155 |
| Farxiga | Dapagliflozin Propanediol | 555 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 530 | 104 |
| Potassium Chloride | Potassium Chloride | 492 | 84 |
| Montelukast Sodium | Montelukast Sodium | 457 | 95 |
| Trulicity | Dulaglutide | 455 | 85 |
| Fluticasone Propionate | Fluticasone Propionate | 452 | 124 |
| Donepezil Hcl | Donepezil Hcl | 442 | 69 |
| Famotidine | Famotidine | 433 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 431 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 414 | 70 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 397 | 78 |
| Naproxen | Naproxen | 387 | 89 |
| Latanoprost | Latanoprost | 363 | 75 |
| Prednisone | Prednisone | 361 | 110 |
| Olanzapine | Olanzapine | 351 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 346 | 85 |
| Divalproex Sodium | Divalproex Sodium | 341 | 53 |
| Oxycodone Hcl | Oxycodone Hcl | 337 | 64 |
| Bumetanide | Bumetanide | 331 | 63 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 330 | 76 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 330 | 99 |
| Glipizide | Glipizide | 327 | 81 |
| Buspirone Hcl | Buspirone Hcl | 324 | 49 |
| Allopurinol | Allopurinol | 320 | 53 |
| Risperidone | Risperidone | 315 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 313 | 95 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 311 | 67 |
| Endocet | Oxycodone Hcl/Acetaminophen | 299 | 60 |
| Hydralazine Hcl | Hydralazine Hcl | 292 | 67 |
| Ozempic | Semaglutide | 292 | 54 |
| Finasteride | Finasteride | 286 | 47 |
| Promethazine Hcl | Promethazine Hcl | 270 | 62 |
| Entresto | Sacubitril/Valsartan | 262 | 41 |
| Amiodarone Hcl | Amiodarone Hcl | 258 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 257 | 67 |
| Azithromycin | Azithromycin | 247 | 129 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 238 | 48 |
| Glipizide Er | Glipizide | 228 | 72 |
| Clonidine Hcl | Clonidine Hcl | 223 | 49 |
| Spironolactone | Spironolactone | 214 | 53 |
| Aripiprazole | Aripiprazole | 210 | 34 |
| Januvia | Sitagliptin Phosphate | 210 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 207 | 78 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 204 | 74 |
| Meclizine Hcl | Meclizine Hcl | 202 | 40 |
| Meloxicam | Meloxicam | 201 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 35 |
| Alprazolam | Alprazolam | 186 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 184 | 25 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 183 | 45 |
| Ondansetron Hcl | Ondansetron Hcl | 181 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 32 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 180 | 55 |
| Nitroglycerin | Nitroglycerin | 178 | 54 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 177 | 38 |
| Enoxaparin Sodium | Enoxaparin Sodium | 172 | 30 |
| Hydrocortisone | Hydrocortisone | 171 | 30 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 170 | 34 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 165 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 163 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 162 | 25 |
| Lorazepam | Lorazepam | 161 | 36 |
| Memantine Hcl | Memantine Hcl | 161 | 26 |
| Tramadol Hcl | Tramadol Hcl | 156 | 42 |
| Linzess | Linaclotide | 150 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 147 | 45 |
| Breo Ellipta | Fluticasone/Vilanterol | 138 | 35 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 137 | suppressed |
| Fluconazole | Fluconazole | 136 | 42 |
| Ventolin Hfa | Albuterol Sulfate | 136 | 47 |
| Alcohol Pads | Alcohol Antiseptic Pads | 133 | 32 |
| Ezetimibe | Ezetimibe | 132 | 32 |
| Topiramate | Topiramate | 132 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 131 | 48 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 130 | 37 |
| Valsartan | Valsartan | 129 | 40 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 128 | 76 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 127 | 74 |
| Albuterol Sulfate | Albuterol Sulfate | 123 | 56 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 123 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 123 | 31 |
| Brimonidine Tartrate | Brimonidine Tartrate | 122 | 24 |
| Lactulose | Lactulose | 122 | 25 |
| Alendronate Sodium | Alendronate Sodium | 119 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 117 | 17 |
| Metformin Hcl Er | Metformin Hcl | 117 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 116 | 20 |
| Incruse Ellipta | Umeclidinium Bromide | 111 | 26 |
| Lidocaine | Lidocaine | 109 | 39 |
| Novolog Flexpen | Insulin Aspart | 109 | 29 |
| Sevelamer Carbonate | Sevelamer Carbonate | 108 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 106 | 24 |
| Lansoprazole | Lansoprazole | 106 | 31 |
| Cephalexin | Cephalexin | 104 | 51 |
| Novolog | Insulin Aspart | 104 | 24 |
| Nystatin | Nystatin | 104 | 47 |
| Colchicine | Colchicine | 102 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 65 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 19 |
| Ketoconazole | Ketoconazole | 98 | 36 |
| Doxepin Hcl | Doxepin Hcl | 97 | 22 |
| Ammonium Lactate | Ammonium Lactate | 96 | 34 |
| Divalproex Sodium Er | Divalproex Sodium | 95 | suppressed |
| Haloperidol | Haloperidol | 94 | 17 |
| Lamotrigine | Lamotrigine | 94 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 26 |
| Lovastatin | Lovastatin | 93 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 93 | 17 |
| Pregabalin | Pregabalin | 92 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 91 | 20 |
| Calcitriol | Calcitriol | 91 | 14 |
| Insulin Lispro | Insulin Lispro | 91 | 38 |
| Tradjenta | Linagliptin | 91 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 90 | 31 |
| Clonazepam | Clonazepam | 88 | 20 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 88 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 85 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 19 |
| Single Use Swab | Alcohol Antiseptic Pads | 84 | 29 |
| Bupropion Xl | Bupropion Hcl | 82 | 14 |
| Glimepiride | Glimepiride | 82 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 19 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 81 | 17 |
| Carbamazepine | Carbamazepine | 81 | suppressed |
| Celecoxib | Celecoxib | 81 | 15 |
| Santyl | Collagenase Clostridium Hist. | 81 | 44 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 80 | 23 |
| Myrbetriq | Mirabegron | 79 | 13 |
| Amoxicillin | Amoxicillin | 77 | 47 |
| Midodrine Hcl | Midodrine Hcl | 75 | 25 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 74 | 18 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 70 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 12 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 67 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 67 | 26 |
| Insulin Aspart Flexpen | Insulin Aspart | 67 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 24 |
| Irbesartan | Irbesartan | 65 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 65 | 19 |
| Timolol Maleate | Timolol Maleate | 65 | 19 |
| Torsemide | Torsemide | 64 | 12 |
| Chlorthalidone | Chlorthalidone | 62 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 62 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Calcium Acetate | Calcium Acetate | 61 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 34 |
| Oxcarbazepine | Oxcarbazepine | 61 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 61 | 21 |
| Scopolamine | Scopolamine | 59 | 12 |
| Levofloxacin | Levofloxacin | 57 | 35 |
| Atenolol | Atenolol | 56 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 14 |
| Budesonide | Budesonide | 55 | 13 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 55 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 55 | 19 |
| Digoxin | Digoxin | 54 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 54 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 54 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 11 |
| Humalog | Insulin Lispro | 53 | 17 |
| Fenofibrate | Fenofibrate | 51 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 51 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 51 | suppressed |
| Clonidine | Clonidine | 50 | suppressed |
| Lacosamide | Lacosamide | 50 | 14 |
| Loperamide | Loperamide Hcl | 50 | 16 |
| Methimazole | Methimazole | 48 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 47 | 15 |
| Mupirocin | Mupirocin | 47 | 26 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 46 | suppressed |
| Glucagon Emergency Kit | Glucagon | 46 | 22 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 45 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 45 | suppressed |
| Xifaxan | Rifaximin | 45 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 44 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 43 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 43 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 41 | 19 |
| Procrit | Epoetin Alfa | 41 | suppressed |
| Insulin Aspart | Insulin Aspart | 40 | 15 |
| Levemir Flexpen | Insulin Detemir | 40 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 14 |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Bicalutamide | Bicalutamide | 38 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 38 | suppressed |
| Acyclovir | Acyclovir | 37 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 37 | suppressed |
| Clozapine | Clozapine | 37 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Sulfasalazine | Sulfasalazine | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 11 |
| Prazosin Hcl | Prazosin Hcl | 35 | suppressed |
| Tacrolimus | Tacrolimus | 35 | suppressed |
| Acetazolamide | Acetazolamide | 34 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 34 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 34 | suppressed |
| Nystop | Nystatin | 34 | 18 |
| Restasis | Cyclosporine | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | suppressed |
| Brilinta | Ticagrelor | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 31 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 31 | suppressed |
| Zonisamide | Zonisamide | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 30 | 12 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 29 | suppressed |
| Humulin R | Insulin Regular, Human | 29 | suppressed |
| Ibu | Ibuprofen | 29 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 28 | 14 |
| Gemtesa | Vibegron | 28 | suppressed |
| Hydroxyurea | Hydroxyurea | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 27 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 27 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 26 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 26 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 26 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 26 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 25 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 25 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Tivicay | Dolutegravir Sodium | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 22 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 22 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 21 |
| Perphenazine | Perphenazine | 22 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 22 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | 14 |
| Telmisartan | Telmisartan | 22 | suppressed |
| Dalfampridine Er | Dalfampridine | 21 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | 11 |
| Letrozole | Letrozole | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 16 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Rhopressa | Netarsudil Mesylate | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valproic Acid | Valproic Acid | 20 | suppressed |
| Admelog | Insulin Lispro | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Renvela | Sevelamer Carbonate | 19 | suppressed |
| Travoprost | Travoprost | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 18 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 18 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Isoniazid | Isoniazid | 18 | suppressed |
| Ofloxacin | Ofloxacin | 18 | 17 |
| Cilostazol | Cilostazol | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 16 | 15 |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Paliperidone Er | Paliperidone | 16 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 16 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Daptomycin | Daptomycin | 15 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 15 | suppressed |
| Nyamyc | Nystatin | 15 | 11 |
| Permethrin | Permethrin | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Pulmicort Flexhaler | Budesonide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Brinzolamide | Brinzolamide | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Zerbaxa | Ceftolozane/Tazobactam | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rifampin | Rifampin | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Xiidra | Lifitegrast | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Exemestane | Exemestane | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tetrabenazine | Tetrabenazine | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,657.29 · 78 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABRYSVO, AREXVY, AUSTEDO XR, BREZTRI, BRIXADI, Belbuca, CAMZYOS, CAPLYTA, COBENFY, COMIRNATY, CREON, Cologuard Collection Kit, DOVATO, FASENRA, INGREZZA, JARDIANCE, Kerendia, Korlym, LINZESS, LOKELMA, MAVYRET, MOUNJARO, NURTEC ODT, NUZYRA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, SKYCLARYS, SUBLOCADE, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error